Rehana Rab
Adult Health · Paterson, NJNPI 1568806271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 263 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 24.6% of the total. Among adult health clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $47.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Boehringer Ingelheim$2K
- Novo Nordisk$1K
- GSK$937
- Bayer$830
- Amgen$652
- plus $3K from 17 others
What the payments were for
- Food & beverage$12,448100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 38 | $3,067 |
| Boehringer Ingelheim | 41 | $2,380 |
| Novo Nordisk | 39 | $1,378 |
| GSK | 25 | $937 |
| Bayer | 25 | $830 |
| Amgen | 8 | $652 |
| Teva Pharmaceuticals USA, Inc. | 10 | $651 |
| Ironwood Pharmaceuticals, Inc | 7 | $607 |
| Lilly USA, LLC | 24 | $417 |
| AbbVie | 11 | $390 |
| Johnson & Johnson(2 entities) | 3 | $319 |
| Pfizer | 10 | $158 |
| Viatris Specialty LLC | 1 | $122 |
| Gilead | 1 | $122 |
| Dexcom, Inc. | 5 | $110 |
| Otsuka America Pharmaceutical, Inc. | 1 | $109 |
| Sanofi-aventis U.S. LLC | 4 | $54 |
| Merck | 2 | $35 |
| Novartis | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,455 in reported general payments places this provider in the 95th percentile of 1,135 adult health providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 181 | $163,126 |
| Diclofenac Sodium | 115 | $62,898 |
| OzempicSemaglutide | 64 | $60,262 |
| JardianceEmpagliflozin | 62 | $50,577 |
| JanuviaSitagliptin Phosphate | 41 | $33,834 |
| TrulicityDulaglutide | 25 | $23,597 |
| EliquisApixaban | 25 | $18,984 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $17,003 |
| KerendiaFinerenone | 18 | $15,258 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 27 | $11,830 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $10,762 |
| DapagliflozinDapagliflozin Propanediol | 19 | $9,446 |
| MyrbetriqMirabegron | 14 | $8,438 |
| TradjentaLinagliptin | 17 | $8,321 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $3,067 | $170,101193 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $2,380 | $65,18890 claims |
| Novo NordiskOzempic | $1,378 | $60,26264 claims |
| MerckJanuvia, Steglatro | $35 | $37,64252 claims |
| Lilly USA, LLCTrulicity | $417 | $23,59725 claims |
| PfizerEliquis | $158 | $18,98425 claims |
| GSKTrelegy Ellipta | $937 | $17,00325 claims |
| BayerKerendia | $830 | $15,25818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Paterson
- Denia PerezPaterson$14K
- Andrea Romero GarcesPaterson$9K
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.